🧾 What This Document Is

This is a 6-K filing, which is a report foreign companies like Canadian-based Organigram must file with the SEC to share major news with U.S. investors. This specific report announces two things: 1) Their shareholders have officially approved a major acquisition, and 2) The results from their annual shareholder meeting. Think of it as the official "yes, it happened" announcement.

🏢 What The Company Does

👉 In simple terms, Organigram Global Inc. (OGI) is a major Canadian cannabis company. They grow and sell cannabis products for adults, focusing on high-quality brands like Edison and SHRED. They've also expanded into cannabis drinks in the U.S. and Canada. They operate several large facilities across Canada and are now making a big move to become a global player.

💰 Financial & Strategic Highlights of the Deal

The big news is that shareholders approved the acquisition of Sanity Group GmbH, a German cannabis company. This isn't just about buying another company; it's a major strategic play.

• The Vote: Shareholders approved the deal with an overwhelming 93% of the vote (excluding certain votes from investor BAT).
• What Organigram Gets: Sanity makes money (positive EBITDA in 2025) and makes the deal financially "accretive" (meaning it's expected to boost Organigram's profits). More importantly, it instantly makes Organigram a top company in the German medical cannabis market, the second-largest legal market in the world.
• European Hub: This gives Organigram a vertically integrated base in Europe, including strategic partners and valuable regulatory experience. They even get a foothold in Switzerland, which is running pioneering cannabis pilot projects.
• The Cost: As part of the deal, Organigram will issue up to 96,287,602 new shares to Sanity's shareholders and to British American Tobacco (BAT), a major existing investor.

👉 Why it matters: This acquisition is a shortcut to global leadership. Instead of building slowly in Europe, Organigram is buying an established platform to immediately compete there and bring its brands to a whole new market.

🚀 Key Moves & Governance Results

Beyond the big acquisition vote, the Annual General & Special Meeting (AGM) had other important results:

• All 10 Directors Elected: Every single board member nominee was re-elected with strong support (between 98.3% and 98.7% of votes in favor). This shows strong shareholder confidence in the current leadership team.
• Auditor Re-appointed: Shareholders voted 97% in favor to keep the accounting firm PricewaterhouseCoopers LLP as their auditor.
• Incentive Plan Approved: A resolution to approve future awards under the company's employee stock plan passed with 94% support. This allows the company to continue using equity to attract and retain talent.

⏳ What's Next

The deal isn't done yet. It's now waiting on a few final conditions:

1. Completing a related private investment (Private Placement).
2. Finalizing new credit facilities with ATB Financial. The company expects to close the acquisition in April 2026. They already received the necessary foreign investment approval earlier.

🌍 Big Picture: Strengths & Risks

👍 Strengths:

• Market Leadership: Solidifies their #1 position in Canada and gives them a top spot in crucial German market.
• Strategic Growth: This is a clear, accretive move into international markets with high growth potential.
• Shareholder Support: The deal passed with a 93% vote, showing strong investor belief in the strategy.

⚠️ Risks & Considerations:

• Execution Risk: Integrating a large company in a different country is complex and challenging.
• Regulatory Risk: The global cannabis industry is heavily regulated, and laws can change quickly.
• Dilution: Issuing nearly 100 million new shares will dilute existing shareholders' ownership of the company.

🧠 The Analogy

Organigram is like a top Canadian university that just acquired a prestigious European campus. They didn't just build a new study-abroad center; they bought an entire, operational university with its own students, professors, and reputation, instantly making them a global educational powerhouse.

📇 Key Contacts & People

For investor relations, the contact is: Max Schwartz Director of Investor Relations Email: [email protected]

🧩 Final Takeaway

Organigram shareholders have given a massive green light to the company's boldest international move yet. By acquiring Sanity Group, they are not just buying revenue; they are buying a fast-track ticket to becoming a dominant global cannabis company, with Europe as their next major battlefield. The next key milestone is the final closing, expected next month.